Quadruple Therapy With Elotuzumab + RVD in Newly Diagnosed MM: Phase IIa Study

June 2-6, 2017; Chicago, Illinois
Addition of elotuzumab to RVD associated with high level of overall response in newly diagnosed patients with MM but higher than expected toxicity.
Format: Microsoft PowerPoint (.ppt)
File Size: 662 KB
Released: June 7, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Downloadable slideset on the current treatment landscape for patients with relapsed and refractory follicular lymphoma, from Clinical Care Options (CCO)

John M. Burke, MD Released: June 17, 2021

Download these expert-selected slides on novel investigational treatments and MRD testing in AML, by Clinical Care Options (CCO)

Eunice S. Wang, MD Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue